Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today that it ...

No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for bankruptcy. There’s never a dull ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Injectable medications originally developed for the treatment of diabetes are also effective for weight loss and have surged ...

(NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ascending dose (MAD) trial of DA-1726 in obesity.

The once-daily version of the pill was in early-stage testing, with researchers trying to figure out the best dose for patients ... But leading treatments like Zepbound and Novo Nordisk’s Wegovy are ...

But as a doctor I am very concerned that the mad scramble to get hold of semaglutide (brand names Ozempic and Wegovy ... consider reducing your dosage of the GLP-1 drug. Speak to your doctor ...

John Fetterman (D-Pa.) on Wednesday called on the Trump administration to back a Biden-era rule that would expand access to GLP-1 medications, such as Ozempic and Wegovy, for millions of Medicare ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type ... it’s really important to work with a doctor on dosing of both the GLP-1 and insulin. Shah says he would caution people ...

This was a mistake. These drugs, like Ozempic and Wegovy, can be a game changer.” Fetterman says he has lost 20 pounds and is not being paid for discussing his treatment. “I’m just a guy who ...